Opko Health, Inc. Contracts & Agreements

Note Purchase Agreement dated July 17, 2024 by and among the Company, certain purchasers party thereto, OPKO Biologics Limited, Eirgen Pharma Ltd. and HCR Injection SPV, LLC as... (Filed With SEC on August 7, 2024)

Form of Note dated July 17, 2024 (Filed With SEC on August 7, 2024)

Asset Purchase Agreement, dated as of March 27, 2024 by and among BioReference Health, LLC, OPKO Health, Inc. and Laboratory Corporation of America Holdings (Filed With SEC on March 28, 2024)

Indenture, dated January 9, 2024, by and between OPKO Health, Inc. and U.S. Bank Trust Company, National Association, as Trustee (Filed With SEC on January 9, 2024)

Purchase Agreement, dated January 4, 2024, by and between the Company and J.P. Morgan Securities LLC, as representative of the Initial Purchasers named therein (Filed With SEC on January 9, 2024)

Convertible Note Purchase Agreement, dated as of January 4, 2024, by and among the Company and certain investors, including Frost Gamma Investments Trust and Jane H. Hsiao, Ph.D.,... (Filed With SEC on January 9, 2024)

License and Research Collaboration Agreement by and between ModeX Therapeutics, Inc., OPKO Health, Inc. (with respect to certain sections), and Merck Sharp & Dohme LLC dated March... (Filed With SEC on May 3, 2023)

Form of Amended 5% Convertible Promissory Note dated February 10, 2023 (Filed With SEC on February 27, 2023)

Severance Agreement and General Release, dated August 16, 2022, by and among OPKO Health, Inc., BioReference Health, LLC and Jon R. Cohen, M.D (Filed With SEC on August 16, 2022)

Settlement Agreement, dated July 14, 2022, by and among OPKO Health, Inc., BioReference Health, LLC, the United States of America, acting through the United States Department of... (Filed With SEC on July 15, 2022)

Corporate Integrity Agreement, dated July 14, 2022, by and among OPKO Health, Inc., BioReference Health, LLC and the Office of Inspector General of the United States Department of... (Filed With SEC on July 15, 2022)

Agreement and Plan of Merger, dated as of May 9, 2022, by and among the Company, ModeX Therapeutics, Inc., Orca Acquisition Sub, Inc. and Gary J. Nabel, solely in the capacity of... (Filed With SEC on May 13, 2022)

Lock-up and Voting Agreement, dated as of May 9, 2022, by and among the Company, Dr. Phillip Frost, Dr. Jane Hsiao and Frost Gamma Investments Trust (Filed With SEC on May 13, 2022)

Offer Letter, dated May 9, 2022, by and between the Company and Dr. Zerhouni (Filed With SEC on May 13, 2022)

Offer Letter, dated May 9. 2022, by and between the Company and Dr. Nabel (Filed With SEC on May 13, 2022)

Waiver Under and Amendment No. 1 to Amended and Restated Credit Agreement, dated as of April 29, 2022, by and among BioReference Health LLC, GeneDx, LLC, the other subsidiary... (Filed With SEC on May 4, 2022)

Asset Purchase Agreement, dated June 16, 2021, among EirGen Pharma Limited, Horizon Therapeutics Ireland DAC, and OPKO Health, Inc. (with respect to certain sections) (Filed With SEC on July 29, 2021)

License Agreement by and among EirGen Pharma Limited and Nicoya Macua Limited, dated June 18, 2021 (Filed With SEC on July 29, 2021)

Exclusive License Agreement by and between OPKO Health, Inc. and CAMP4 Therapeutics Corporation, dated July 6, 2021 (Filed With SEC on July 29, 2021)

Form of Exchange Agreement, dated as of May 6, 2021, by and between OPKO Health Inc. and the applicable Noteholder (Filed With SEC on May 7, 2021)

Amendment No. 12 to Credit Agreement, dated as of March 12, 2021, by and among BioReference Laboratories, Inc., certain of its subsidiaries, and JPMorgan Chase Bank, N.A (Filed With SEC on March 17, 2021)

Description of Securities (Filed With SEC on February 18, 2021)

Amendment to Development and License Agreement between EirGen Pharma Ltd. and Vifor Fresenius Medical Care Renal Pharma Ltd., dated May 5, 2020 (Filed With SEC on July 31, 2020)

Description of Securities (Filed With SEC on March 2, 2020)

Amendment No. 10 to Credit Agreement by and between BioReference Laboratories, Inc. and certain of its subsidiaries, and JPMorgan Chase, N.A. dated November 4, 2019 (Filed With SEC on March 2, 2020)

Amendment No. 11 to Credit Agreement by and between BioReference Laboratories, Inc. and certain of its subsidiaries, and JPMorgan Chase, N.A. dated February 25, 2020 (Filed With SEC on March 2, 2020)

Credit Agreement, dated as of February 25, 2020, by and between OPKO Health, Inc. and Frost Gamma Investment Trust (Filed With SEC on March 2, 2020)

Amendment No. 9 to Credit Agreement by and between BioReference Laboratories, Inc. and certain of its subsidiaries, and JPMorgan Chase, N.A. dated August 6, 2019 (Filed With SEC on November 5, 2019)

Underwriting Agreement, dated February 4, 2019, by and between the Company and Jefferies LLC (Filed With SEC on October 29, 2019)

Amendment No. 8 to Credit Agreement by and between BioReference Laboratories, Inc. and certain of its subsidiaries, and JPMorgan Chase, N.A. dated February 26, 2019 (Filed With SEC on May 8, 2019)

Credit Agreement, dated as of November 8, 2018, by and between the OPKO Health, Inc. and Frost Gamma Investments Trust (Filed With SEC on March 1, 2019)

Stock Purchase Agreement, dated as of November 8, 2018, between certain investors and OPKO Health, Inc (Filed With SEC on March 1, 2019)

Underwriting Agreement, dated February 4, 2019, by and between the Company and Jefferies LLC (Filed With SEC on February 7, 2019)

Base Indenture related to the 4.50% Convertible Senior Notes due 2025, dated as of February 7, 2019, by and between the Company and U.S. Bank National Association, as trustee (Filed With SEC on February 7, 2019)

Form of 4.50% Convertible Senior Notes due 2025 (incorporated herein by reference to Exhibit A of the First Supplemental Indenture filed as Exhibit 4.3 to this Current Report on... (Filed With SEC on February 7, 2019)

Share Lending Agreement, dated February 4, 2019, by and between the Company and Jefferies Capital Services, LLC (Filed With SEC on February 7, 2019)

Amendment No. 7 to Credit Agreement by and between BioReference Laboratories, Inc. and certain of its subsidiaries, and JPMorgan Chase, N.A. dated February 28, 2018 (Filed With SEC on August 7, 2018)

Development and License Agreement by and between EirGen Pharma Limited, a subsidiary of OPKO Health, Inc., and Japan Tobacco Inc., dated October 12, 2017 (Filed With SEC on March 1, 2018)

Amendment No. 5 to Credit Agreement, dated as of November 8, 2017, among Bio-Reference Laboratories, Inc. and certain of its subsidiaries and JPMorgan Chase Bank, N.A (Filed With SEC on March 1, 2018)

Amendment No. 6 to Credit Agreement, dated as of December 22, 2017, among Bio-Reference Laboratories, Inc. and certain of its subsidiaries and JPMorgan Chase Bank, N.A (Filed With SEC on March 1, 2018)

Form of 5% Convertible Promissory Note dated February 27, 2018 (Filed With SEC on March 1, 2018)

Amendment No. 4 to Credit Agreement by and between Bio-Reference Laboratories, Inc. and certain of its subsidiaries and JPMorgan Chase Bank, N.A. dated August 7, 2017 (Filed With SEC on November 8, 2017)

Commitment Letter by and between OPKO Health, Inc. and Veterans Accountable Care Group, LLC, dated August 15, 2017 (Filed With SEC on November 8, 2017)

AMENDMENT NO. 3 TO CREDIT AGREEMENT (Filed With SEC on March 23, 2017)

DEVELOPMENT AND LICENSE AGREEMENT BETWEEN OPKO HEALTH, INC. AND VIFOR FRESENIUS MEDICAL CARE RENAL PHARMA LTD May 8, 2016 (Filed With SEC on August 8, 2016)

ARRANGEMENT AGREEMENT BY AND AMONG OPKOHEALTH, INC., OPKO GLOBAL HOLDINGS, INC. AND TRANSITIONTHERAPEUTICS INC. Dated as of June 29, 2016 TABLE OF CONTENTS (Filed With SEC on June 30, 2016)

CREDIT AGREEMENT dated as of November 5, 2015, among BIO-REFERENCE LABORATORIES, INC., as the Company, The Subsidiaries from time to time party hereto as Subsidiary Borrowers, The... (Filed With SEC on February 29, 2016)

DATED 5 May, 2015 (1) SELLERS (2) OPKO IRELAND LIMITED (3) OPKO HEALTH, INC. AGREEMENT FOR THE SALE AND PURCHASE OF SHARES IN EIRGEN PHARMA LIMITED McCann FitzGerald Solicitors... (Filed With SEC on August 5, 2015)

DATED 5 May 2015 (1) SELLERS (2) OPKO IRELAND LIMITED FORM OF AGREEMENT FOR THE SALE AND PURCHASE OF SHARES IN EIRGEN PHARMA LIMITED McCann FitzGerald Solicitors Riverside One Sir... (Filed With SEC on August 5, 2015)

AGREEMENT AND PLAN OF MERGER BY AND AMONG OPKO HEALTH, INC., BAMBOO ACQUISITION, INC. AND BIO-REFERENCE LABORATORIES, INC. Dated as of June 3, 2015 TABLE OF CONTENTS (Filed With SEC on June 4, 2015)

*** = Portions of this exhibit have been omitted pursuant to a request for confidential treatment. An unredacted version of this exhibit has been filed separately with the... (Filed With SEC on February 27, 2015)

AMENDMENT TO THE OPKOHEALTH, INC. 2007 EQUITY INCENTIVE PLAN (Filed With SEC on August 30, 2013)

SHARE PURCHASE AGREEMENT BY AND AMONG CYTOCHROMA INC., CYTOCHROMA HOLDINGS ULC, CYTOCHROMA CANADA INC. CYTOCHROMA DEVELOPMENT INC. PROVENTIV THERAPEUTICS, LLC CYTOCHROMA CAYMAN... (Filed With SEC on May 10, 2013)

AGREEMENT AND PLAN OF MERGER (Filed With SEC on March 18, 2013)

OPKO HEALTH, INC. 3.00% CONVERTIBLE SENIOR NOTES DUE 2033 INDENTURE DATED AS OF JANUARY 30, 2013 WELLS FARGOBANK, NATIONAL ASSOCIATION TRUSTEE Table of Contents (Filed With SEC on February 5, 2013)

NOTE PURCHASE AGREEMENT (Filed With SEC on January 29, 2013)

STOCK PURCHASE AGREEMENT (Filed With SEC on November 9, 2012)

STOCK PURCHASE AGREEMENT (Filed With SEC on March 15, 2012)

AGREEMENT AND PLAN OF MERGER (Filed With SEC on November 9, 2011)

ASSET PURCHASE AGREEMENT (Filed With SEC on November 9, 2011)

We have a history of operating losses and we do not expect to become profitable in the near future (Filed With SEC on May 10, 2011)

We have a history of operating losses and we do not expect to become profitable in the near future (Filed With SEC on March 16, 2011)

We have a history of operating losses and we do not expect to become profitable in the near future (Filed With SEC on May 10, 2010)

We have a history of operating losses and we do not expect to become profitable in the near future (Filed With SEC on March 17, 2010)

FORM OF RESTRICTED STOCK AGREEMENT FOR DIRECTORS (Filed With SEC on November 9, 2009)

R E C I T A L S (Filed With SEC on November 9, 2009)

SECURITIES PURCHASE AGREEMENT dated as of September 18, 2009 by and among OPKO HEALTH, INC. AND THE PURCHASERS SET FORTH ON THE SIGNATURE PAGES HERETO (Filed With SEC on September 24, 2009)

COMMON STOCK WARRANT (Filed With SEC on September 24, 2009)

We have a history of operating losses and we do not expect to become profitable in the near future (Filed With SEC on August 7, 2009)

EX-31.1 Section 302 Certification of CEO (Filed With SEC on May 8, 2009)

STOCK PURCHASE AGREEMENT (Filed With SEC on November 12, 2008)

CONFIDENTIAL MATERIAL OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. ASTERISKS DENOTE SUCH OMISSIONS. SECURITIES PURCHASE AGREEMENT (Filed With SEC on August 8, 2008)

DIRECTOR INDEMNIFICATION AGREEMENT (Filed With SEC on August 8, 2008)

OFFICER INDEMNIFICATION AGREEMENT (Filed With SEC on August 8, 2008)

AMENDED AND RESTATED BYLAWS OF OPKO HEALTH, INC. (A DELAWARE CORPORATION) Effective: March 28, 2008 Article I. OFFICES (Filed With SEC on March 31, 2008)

OPHTHALMIC TECHNOLOGIES INC. SHARE PURCHASE AGREEMENT April11, 2007 OPHTHALMIC TECHNOLOGIES INC SHARE PURCHASE AGREEMENT (Filed With SEC on March 31, 2008)

SHARE PURCHASE AGREEMENT November 28, 2007 (Filed With SEC on March 31, 2008)

OPKO HEALTH, INC. - and - OTI HOLDINGS LIMITED - and - EACH HOLDER OF EXCHANGEABLE SHARES in the capital of OTI Holdings Limited EXCHANGE AND SUPPORT AGREEMENT DATED: November 28,... (Filed With SEC on March 31, 2008)

STOCK PURCHASE AGREEMENT (Filed With SEC on March 31, 2008)

OPKO HEALTH, INC. 2007 EQUITY INCENTIVE PLAN (Filed With SEC on March 31, 2008)

OFFICE LEASE (Filed With SEC on November 14, 2007)

SETTLEMENT AGREEMENT AND GENERAL RELEASE (Filed With SEC on May 11, 2007)

EXEGENICS INC. 4400 Biscayne Blvd. Suite 900 Miami, Florida 33137 (Filed With SEC on April 13, 2007)

MERGER AGREEMENT AND PLAN OF REORGANIZATION (Filed With SEC on April 2, 2007)

FORM OF COMMON STOCK WARRANT (Filed With SEC on April 2, 2007)

FORM OF SERIES C PREFERRED STOCK WARRANT (Filed With SEC on April 2, 2007)

FORM OF LOCKUP AGREEMENT (Filed With SEC on April 2, 2007)

CREDIT AGREEMENT (Filed With SEC on April 2, 2007)

AMENDED AND RESTATED VENTURE LOAN AND SECURITY AGREEMENT Executed as of March ___, 2007 Effective as of September 14, 2005 by and among (Filed With SEC on April 2, 2007)

TECHNOLOGY LICENSE AGREEMENT (Filed With SEC on April 2, 2007)

LICENSE AGREEMENT (Filed With SEC on April 2, 2007)

AMENDMENT NO. 1 TO LICENSE AGREEMENT (Filed With SEC on April 2, 2007)

AMENDMENT NO. 2 TO LICENSE AGREEMENT (Filed With SEC on April 2, 2007)

LICENSE AND COLLABORATION AGREEMENT (Filed With SEC on April 2, 2007)

University of Pennsylvania (Filed With SEC on April 2, 2007)

First Amendment to the License Agreement between the The Trustees of the University of Pennsylvania and Acuity Pharmaceuticals, Inc. (Filed With SEC on April 2, 2007)

FirstAmendment to the License Agreement between the The Trustees of the University of Pennsylvania and Acuity Pharmaceuticals, Inc. (Filed With SEC on April 2, 2007)

AMENDED AND RESTATED SUBORDINATION AGREEMENT (Filed With SEC on April 2, 2007)

EXEGENICS INC. 4400 Biscayne Blvd Suite 900 Miami, Florida 33137 (Filed With SEC on April 2, 2007)

EMPLOYMENT AGREEMENT (Filed With SEC on April 2, 2007)

AMENDMENT TO STOCK PURCHASE AGREEMENT (Filed With SEC on December 4, 2006)

STOCK PURCHASE AGREEMENT (Filed With SEC on August 15, 2006)

EX-10.1 Separation Agreement (Filed With SEC on August 15, 2005)

EX-10.2 Agreement Between eXegenics and D. Hostelley (Filed With SEC on August 15, 2005)

INTELLECTUAL PROPERTY ASSIGNMENT AGREEMENT (Filed With SEC on September 10, 2004)

SUBLEASE (Filed With SEC on August 16, 2004)

Form of Warrant Agreement - Gruntal & Co., LLC (Filed With SEC on May 14, 2004)

Form of Warrant Agreement - Roan Meyers Associates (Filed With SEC on May 14, 2004)

Form of Warrant Agreement - Petkevich & Partners (Filed With SEC on May 14, 2004)

Promissory Note and Pledge Agreement (Filed With SEC on April 7, 2004)

Amendment to Employment Agreement - David E Riggs (Filed With SEC on April 7, 2004)

Termination Letter - Dorit Arad (Filed With SEC on April 7, 2004)

Termination Letter - Joan Gillett (Filed With SEC on April 7, 2004)

Separation from Employment Letter - Arthur Bollon (Filed With SEC on April 7, 2004)

EX-10.1 Amendment to Employment Agreement (Filed With SEC on November 14, 2003)

EX-10.2 Amendment to Employment Agreement (Filed With SEC on November 14, 2003)

Category

Industry

Companies

Contracts

Opko Health, Inc. Contracts & Agreements